prasinezumab

{{Short description|Experimental monoclonal antibody}}

{{Infobox drug

| type = mab

| image =

| width =

| alt =

| caption =

| mab_type =

| source =

| target = α-Synuclein

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| DailyMedID =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration =

| class =

| ATC_prefix =

| ATC_suffix =

| ATC_supplemental =

| biosimilars =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1960462-19-4

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank = DB14788

| ChemSpiderID =

| UNII = P3Z0Z3P1ZI

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = NEOD002; NEOD-002; PRX002; PRX-002; RG7935; RG-7935; RO7046015; RO-7046015

| IUPAC_name =

| C = | H = | N = | O = | S =

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Prasinezumab ({{Abbrlink|INN|International Nonproprietary Name}}, {{Abbrlink|USAN|United States Adopted Name}}; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease.{{cite web | title=Prasinezumab - Prothena Corporation/Roche | website=AdisInsight | date=9 May 2024 | url=https://adisinsight.springer.com/drugs/800040327 | access-date=26 September 2024}}{{cite journal | vauthors = Manoutcharian K, Gevorkian G | title = Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease | journal = BioDrugs | volume = 38 | issue = 2 | pages = 249–257 | date = March 2024 | pmid = 38280078 | pmc = 10912140 | doi = 10.1007/s40259-024-00646-5 | url = }}{{cite journal | vauthors = Lasheen NN, Allam S, Elgarawany A, Aswa DW, Mansour R, Farouk Z | title = Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders | journal = J Physiol Sci | volume = 74 | issue = 1 | pages = 46 | date = September 2024 | pmid = 39313800 | pmc = 11421184 | doi = 10.1186/s12576-024-00933-4 | doi-access = free | url = }}{{cite journal | vauthors = Teng JS, Ooi YY, Chye SM, Ling AP, Koh RY | title = Immunotherapies for Parkinson's Disease: Progression of Clinical Development | journal = CNS Neurol Disord Drug Targets | volume = 20 | issue = 9 | pages = 802–813 | date = 2021 | pmid = 34042040 | doi = 10.2174/1871527320666210526160926 | url = }} No significant effect on disease progression was seen in a 52-week phase 2 clinical trial. In any case, the trial was extended and development of the drug continues. There have been concerns about research misconduct and data fabrication relevant to prasinezumab.{{cite web | last=Incorvaia | first=Darren | title=NIH neuroscience leader committed research misconduct, agency investigation finds | website=Fierce Biotech | date=26 September 2024 | url=https://www.fiercebiotech.com/research/head-national-institute-aging-neuroscience-division-eliezer-masliah-found-have-committed | access-date=26 September 2024}} As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease. It is under development by Prothena Biosciences and Roche.